{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:06:45Z","timestamp":1790006805859,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,21]]},"DOI":"10.7759\/cureus.116652","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:53:23Z","timestamp":1790006003000},"source":"Crossref","is-referenced-by-count":0,"title":["Community Experience of COVID-19 Hospitalizations"],"prefix":"10.7759","author":[{"given":"Kourosh","family":"Safai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Frugoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Pisarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylie","family":"Heyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graal","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"David J. Spencer CDC Museum. CDC Museum COVID-19 Timeline. (2025). https.\/\/www.cdc.gov\/museum\/timeline\/covid19.html."},{"key":"ref2","unstructured":"Administration for Strategic Preparedness and Response. Declarations of a public health emergency. (2024). Accessed. Jan 2024: https:\/\/www.aspr.gov\/about\/law-policy-strategy\/emergency-declarations\/declarations-public-health-emergency\/list-phe-d...."},{"key":"ref3","unstructured":"Centers for Disease Control and Prevention. CDC COVID data tracker. Accessed. 20 Nov 2023: https:\/\/stacks.cdc.gov\/view\/cdc\/98212\/cdc_98212_DS1.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00399-6","article-title":"COVID-19: before the fall, an evidence-based narrative review of treatment options","volume":"10","author":"Rebold N","year":"2021","unstructured":"Rebold N, Holger D, Alosaimy S, Morrisette T, Rybak M. COVID-19: before the fall, an evidence-based narrative review of treatment options. Infect Dis Ther. 2021, 10:93-113. 10.1007\/s40121-021-00399-6","journal-title":"Infect Dis Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015201","article-title":"Obesity as an independent risk factor for COVID-19 severity and mortality","volume":"5","author":"Tadayon Najafabadi B","year":"2023","unstructured":"Tadayon Najafabadi B, Rayner DG, Shokraee K, et al.. Obesity as an independent risk factor for COVID-19 severity and mortality. Cochrane Database Syst Rev. 2023, 5:CD015201. 10.1002\/14651858.CD015201","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20176702","article-title":"Spatial variation in COVID-19 mortality in New York City and its association with neighborhood race, ethnicity, and nativity status","volume":"20","author":"Friedman S","year":"2023","unstructured":"Friedman S, Insaf TZ, Adeyeye T, Lee JW. Spatial variation in COVID-19 mortality in New York City and its association with neighborhood race, ethnicity, and nativity status. Int J Environ Res Public Health. 2023, 20:6702. 10.3390\/ijerph20176702","journal-title":"Int J Environ Res Public Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2020.07.007","article-title":"Risk for COVID-19 infection and death among Latinos in the United States: examining heterogeneity in transmission dynamics","volume":"52","author":"Rodriguez-Diaz CE","year":"2020","unstructured":"Rodriguez-Diaz CE, Guilamo-Ramos V, Mena L, et al.. Risk for COVID-19 infection and death among Latinos in the United States: examining heterogeneity in transmission dynamics. Ann Epidemiol. 2020, 52:46-53.e2. 10.1016\/j.annepidem.2020.07.007","journal-title":"Ann Epidemiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2020.05.003","article-title":"Assessing differential impacts of COVID-19 on black communities","volume":"47","author":"Millett GA","year":"2020","unstructured":"Millett GA, Jones AT, Benkeser D, et al.. Assessing differential impacts of COVID-19 on black communities. Ann Epidemiol. 2020, 47:37-44. 10.1016\/j.annepidem.2020.05.003","journal-title":"Ann Epidemiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.34147","article-title":"Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis","volume":"4","author":"Magesh S","year":"2021","unstructured":"Magesh S, John D, Li WT, et al.. Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. JAMA Netw Open. 2021, 4:e2134147. 10.1001\/jamanetworkopen.2021.34147","journal-title":"JAMA Netw Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan WJ","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, et al.. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020, 382:1708-20. 10.1056\/NEJMoa2002032","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01462-5","article-title":"D-dimer, disease severity, and deaths (3D-study) in patients with COVID-19: a systematic review and meta-analysis of 100 studies","volume":"11","author":"Varikasuvu SR","year":"2021","unstructured":"Varikasuvu SR, Varshney S, Dutt N, Munikumar M, Asfahan S, Kulkarni PP, Gupta P. D-dimer, disease severity, and deaths (3D-study) in patients with COVID-19: a systematic review and meta-analysis of 100 studies. Sci Rep. 2021, 11:21888. 10.1038\/s41598-021-01462-5","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50525","article-title":"Monocyte distribution width predicts sepsis, respiratory failure, and death in COVID-19","volume":"15","author":"Frugoli A","year":"2023","unstructured":"Frugoli A, Ong J, Meyer B, Khiatah B, Bernstein R, Hernandez A, Diaz G. Monocyte distribution width predicts sepsis, respiratory failure, and death in COVID-19. Cureus. 2023, 15:e50525. 10.7759\/cureus.50525","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","volume":"324","author":"Li L","year":"2020","unstructured":"Li L, Zhang W, Hu Y, et al.. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020, 324:460-70. 10.1001\/jama.2020.10044","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3201\/eid2803.212299","article-title":"High-dose convalescent plasma for treatment of severe COVID-19","volume":"28","author":"De Santis GC","year":"2022","unstructured":"De Santis GC, Oliveira LC, Garibaldi PM, et al.. High-dose convalescent plasma for treatment of severe COVID-19. Emerg Infect Dis. 2022, 28:548-55. 10.3201\/eid2803.212299","journal-title":"Emerg Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00900-3","article-title":"Remdesivir for the treatment of COVID-19: a narrative review","volume":"13","author":"Godwin PO","year":"2024","unstructured":"Godwin PO, Polsonetti B, Caron MF, Oppelt TF. Remdesivir for the treatment of COVID-19: a narrative review. Infect Dis Ther. 2024, 13:1-19. 10.1007\/s40121-023-00900-3","journal-title":"Infect Dis Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.04.018","article-title":"Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis","volume":"28","author":"Lee TC","year":"2022","unstructured":"Lee TC, Murthy S, Del Corpo O, et al.. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2022, 28:1203-10. 10.1016\/j.cmi.2022.04.018","journal-title":"Clin Microbiol Infect"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad482","article-title":"Remdesivir is associated with reduced mortality in COVID-19 patients requiring supplemental oxygen including invasive mechanical ventilation across SARS-CoV-2 variants","volume":"10","author":"Mozaffari E","year":"2023","unstructured":"Mozaffari E, Chandak A, Gottlieb RL, et al.. Remdesivir is associated with reduced mortality in COVID-19 patients requiring supplemental oxygen including invasive mechanical ventilation across SARS-CoV-2 variants. Open Forum Infect Dis. 2023, 10:ofad482. 10.1093\/ofid\/ofad482","journal-title":"Open Forum Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19-final report","volume":"383","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al.. Remdesivir for the treatment of COVID-19-final report. N Engl J Med. 2020, 383:1813-26. 10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe COVID-19","volume":"383","author":"Goldman JD","year":"2020","unstructured":"Goldman JD, Lye DC, Hui DS, et al.. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med. 2020, 383:1827-37. 10.1056\/NEJMoa2015301","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.44505","article-title":"Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States","volume":"5","author":"Chokkalingam AP","year":"2022","unstructured":"Chokkalingam AP, Hayden J, Goldman JD, et al.. Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States. JAMA Netw Open. 2022, 5:e2244505. 10.1001\/jamanetworkopen.2022.44505","journal-title":"JAMA Netw Open"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe COVID-19 in outpatients","volume":"386","author":"Gottlieb RL","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R, et al.. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022, 386:305-15. 10.1056\/NEJMoa2116846","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Horby P","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, et al.. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021, 384:693-704. 10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.8516","article-title":"Dexamethasone for inpatients with COVID-19 in a national cohort","volume":"6","author":"Mourad A","year":"2023","unstructured":"Mourad A, Thibault D, Holland TL, Yang S, Young AR, Arnold Egloff SA, Thomas LE. Dexamethasone for inpatients with COVID-19 in a national cohort. JAMA Netw Open. 2023, 6:e238516. 10.1001\/jamanetworkopen.2023.8516","journal-title":"JAMA Netw Open"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1177","article-title":"Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial","volume":"72","author":"Jeronimo CM","year":"2021","unstructured":"Jeronimo CM, Farias ME, Val FF, et al.. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021, 72:e373-81. 10.1093\/cid\/ciaa1177","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.17.20133579","article-title":"GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia [PREPRINT]","author":"Corral-Gudino L","unstructured":"Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, et al.. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia [PREPRINT]. medRxiv. 10.1101\/2020.06.17.20133579","journal-title":"medRxiv"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine O","year":"2021","unstructured":"Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021, 181:32-40. 10.1001\/jamainternmed.2020.6820","journal-title":"JAMA Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe COVID-19 pneumonia","volume":"384","author":"Rosas IO","year":"2021","unstructured":"Rosas IO, Br\u00e4u N, Waters M, et al.. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia. N Engl J Med. 2021, 384:1503-16. 10.1056\/NEJMoa2028700","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279208","article-title":"Interventions and outcomes of COVID-19 patients in a community hospital-a single center study comparing the first and second waves","volume":"17","author":"Alebna PL","year":"2022","unstructured":"Alebna PL, Chung J, Rashid M, Hoban D, LaForgia M, Khera S, Loftus M. Interventions and outcomes of COVID-19 patients in a community hospital-a single center study comparing the first and second waves. PLoS One. 2022, 17:e0279208. 10.1371\/journal.pone.0279208","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267468","article-title":"Demographics, comorbidities, and laboratory parameters in hospitalized patients with SARS-CoV2 infection at a community hospital in rural Pennsylvania","volume":"17","author":"Pachpande V","year":"2022","unstructured":"Pachpande V, Senapathi SH, Williams K, Chai S, Mandal S, Prabhu S. Demographics, comorbidities, and laboratory parameters in hospitalized patients with SARS-CoV2 infection at a community hospital in rural Pennsylvania. PLoS One. 2022, 17:e0267468. 10.1371\/journal.pone.0267468","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-08007-0","article-title":"The relationship of COVID-19 vaccination with mortality among 86,732 hospitalized patients: subpopulations, patient factors, and changes over time","volume":"38","author":"Baker TB","year":"2023","unstructured":"Baker TB, Bolt DM, Smith SS, et al.. The relationship of COVID-19 vaccination with mortality among 86,732 hospitalized patients: subpopulations, patient factors, and changes over time. J Gen Intern Med. 2023, 38:1248-55. 10.1007\/s11606-022-08007-0","journal-title":"J Gen Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/514229-community-experience-of-covid-19-hospitalizations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:53:25Z","timestamp":1790006005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/514229-community-experience-of-covid-19-hospitalizations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.116652","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}